Prostate sclerosing adenopathy: A clinicopathological and immunohistochemical study of twelve patients

Figure 4 Immunohistochemistry results. A: AR was strongly expressed in prostate sclerosing adenopathy (Immunohistochemistry; magnification, × 200; scale bar, 50 μm); B: Calponin is positively expressed in prostate sclerosing adenopathy (Immunohistochemistry; magnification, × 200; scale bar, 50 μm); C: CK5/6 is positively expressed in prostate sclerosing adenopathy (Immunohistochemistry; magnification, × 200; scale bar, 50 μm); D: CKH was strongly expressed in prostate sclerosing adenopathy (Immunohistochemistry; magnification, × 200; scale bar, 50 μm); E: P63 was moderately expressed in prostate sclerosing adenopathy (Immunohistochemistry; magnification, × 200; scale bar, 50 μm); F: P504S is not expressed in prostate sclerosing adenopathy (Immunohistochemistry; magnification, × 200; scale bar, 50 μm); G: SMA is moderately expressed in prostatic sclerosing adenopathy (Immunohistochemistry; magnification, × 200; scale bar, 50 μm); H: S100 is strongly expressed in prostate sclerosing adenopathy (Immunohistochemistry; magnification, × 200; scale bar, 50 μm).